Publications by authors named "Amanda Flannery"

Background: Chronic graft-versus-host disease (cGVHD) adversely impacts return to work for adult allogeneic hematopoietic stem cell transplant (HSCT) survivors, but no data exist on children with cGVHD transitioning back to school. We hypothesized that cGVHD adversely impacts broad aspects of school experience of children compared to their allogeneic-HSCT peers without cGVHD.

Methods: We conducted a single center cross-sectional pilot study using a 42-item questionnaire, investigating academic performance and social-emotional aspects of schooling pre- and post-HSCT.

View Article and Find Full Text PDF
Article Synopsis
  • Ruxolitinib is a JAK1/2 inhibitor showing promise for treating chronic graft versus host disease (cGVHD) in children and young adults, though pediatric dosing information has been limited.
  • In a study of 20 patients aged 5 to 26, a dosing strategy of 5 mg or 2.5 mg twice daily was used, resulting in a 70% overall response rate among patients with severe and moderate cGVHD.
  • While most patients had positive responses, there were adverse effects like infections and blood disorders, and two patients unfortunately died from complications related to cGVHD.
View Article and Find Full Text PDF

Background/purpose: Pneumatosis intestinalis (PI) has been reported in hematopoietic stem cell transplant recipients (HSCT) since 1980s and at present there is no uniform consensus of the significance and management of this condition.

Methods: We retrospectively reviewed medical records of 990 consecutive pediatric HSCT recipients and examined data for clinical PI presentation, management and outcomes RESULTS: PI was identified in 53 patients (5.4%), mainly allogeneic HSCT recipients receiving systemic steroids.

View Article and Find Full Text PDF

cGVHD is a significant cause of morbidity and mortality after transplant. Ibrutinib has been studied as treatment for cGVHD in the adult population. Pediatric dosing and safety of ibrutinib are unknown.

View Article and Find Full Text PDF

Non-synostotic deformational plagiocephaly (DP) is a common condition that affects as many as one in five infants in the first 2 months of life. The purpose of this article, the second in a two-part series, is to present a synthesis of the evidence related to management of deformational plagiocephaly and an evidence-based clinical decision tool for multidisciplinary management of DP. We systematically reviewed and graded the literature on management of DP from 2000 to 2011 based on level of evidence and quality.

View Article and Find Full Text PDF

Non-synostotic deformational plagiocephaly (DP) is head asymmetry that results from external forces that mold the skull in the first year of life. Primary care providers are most likely to encounter DP when infants present for well-child care, and for this reason it is important that providers be competent in assessing, diagnosing, and participating in the prevention and management of DP. The purpose of this two-part series on DP is to present an overview of assessment, diagnosis, and evidence-based management of DP for health care providers.

View Article and Find Full Text PDF